The Impact of Dietary Salt on the Severity of Eczema

Conditions

• Atopic Dermatitis
• Eczema

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Sodium chloride tablets — DRUG
  During the 5-week long sodium tablet intervention period, participants will receive five 1 g sodium chloride tablets each morning and four 1 g sodium chloride tablets each evening. Each sodium chloride tablet will contain 0.394 g or 17 mmol of sodium.
• Placebo Tablets — OTHER
  During the 5-week long placebo period, participants will receive five placebo tablets each morning and four placebo tablets each evening

Study Details

The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are: * Does a low-sodium diet improve eczema severity? * How does a low-sodium diet impact skin sodium concentration? * Is skin sodium concentration associated with eczema severity? Researchers will ask all participant to follow a low-sodium diet, then compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake. Participants will: * Follow a low-salt diet for the duration of the 24-week study * Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa * Complete up to 4 virtual check-in visits * Visit the clinic 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI

Key Dates

Start date

Jun 22, 2026

Status verified

Jun 2026

Primary completion

Mar 5, 2028

Completion

May 5, 2028

Study Design

Enrollment

40 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Arms

• Experimental: Sodium tablets first
  Participants will be randomized to receive sodium tablets for weeks 13-17, no tablets for a washout period during weeks 18-19, then placebo tablets for weeks 20-24.
• Experimental: Placebo tablets first
  Participants will be randomized to receive placebo tablets for weeks 13-17, no tablets for a washout period during weeks 18-19, then sodium tablets for weeks 20-24.

Primary Outcome Measure

Eczema severity [ Time Frame: 6 months ]

Central Contacts

• Alicia Hamblin, BS
  925-549-7889
  [email protected]
• Katrina Abuabara, MD
  415-514-9769
  [email protected]

Locations (2)

Find similar trials in San Francisco, CA

Related Studies

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
  PHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
• Molecular Signatures of Cutaneous Dupilumab Response
  PHASE4 · Recruiting · University of California, San Francisco · San Francisco, California
• Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
  Recruiting · University of California, San Diego · La Jolla, California
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  PHASE2 · Recruiting · Pfizer · Birmingham, Alabama